270
Participants
Start Date
May 9, 2023
Primary Completion Date
December 31, 2028
Study Completion Date
June 30, 2031
LYL314
CAR T-cell therapy
Fludarabine
Conditioning chemotherapy
Cyclophosphamide
Conditioning chemotherapy
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
Lehigh Valley Topper Cancer Center Institute, Allentown
RECRUITING
Thomas Jefferson University, Philadelphia
RECRUITING
Virginia Commonwealth University-Massey Cancer Center, Richmond
RECRUITING
Augusta University Medical Center, Augusta
RECRUITING
University of Louisville Brown Cancer Center, Louisville
RECRUITING
University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
RECRUITING
Indiana Blood and Marrow Transplantation, Indianapolis
RECRUITING
Corewell Health, Grand Rapids
RECRUITING
University of Iowa, Iowa City
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
Baylor University Medical Center, Dallas
RECRUITING
Colorado Blood Cancer Institute, Denver
RECRUITING
Huntsman Cancer Institute, Salt Lake City
RECRUITING
Intermountain Healthcare, Salt Lake City
RECRUITING
University of New Mexico Comprehensive Cancer Center, Albuquerque
RECRUITING
Cedars-Sinai Medical Center, Los Angeles
RECRUITING
University of California, Los Angeles (UCLA) Medical Center, Los Angeles
RECRUITING
Scripps Clinic, San Diego
RECRUITING
University of California-Irvine Medical Center, Irvine
Lead Sponsor
Lyell Immunopharma, Inc.
INDUSTRY